The relationship between sleep apnoea and metabolic disease is bidirectional and dose-dependent, meaning both conditions worsen each other, and the worse either one gets, the worse the other tends to become. OSA promotes insulin resistance and weight gain, and excess weight worsens OSA. Breaking that cycle requires treating the sleep problem explicitly rather than assuming that weight loss alone will resolve it, because the hormonal disruption from OSA makes weight loss harder at the same time as OSA makes obesity more metabolically damaging.
Type 2 Diabetes
OSA patients are more than twice as likely to have type 2 diabetes — the odds ratio in a meta-analysis pooling 25 studies and 154,948 patients was 2.29. To put that in real-world terms: type 2 diabetes affects roughly 1 in 12 UK adults. With untreated OSA, that risk rises to approximately 1 in 5. In those under the age of 50, the elevation is considerably higher: more than three times the usual rate — an odds ratio of 3.28. Younger adults with OSA are particularly metabolically vulnerable because they are experiencing these hormonal stresses during years when the body is less forgiving than in later life.
Looking at this from the other direction: OSA is found in 55 to 86 per cent of people already living with type 2 diabetes when they are tested systematically for it. That means between 5 and 8 out of every 10 people with type 2 diabetes have OSA — and most of it is undiagnosed. This matters clinically because if OSA is contributing to the insulin resistance and making blood glucose control harder, treating the sleep problem is a legitimate therapeutic intervention in the management of diabetes, not merely an incidental quality-of-life improvement.
A meta-analysis of 11 randomised controlled trials — the gold standard of medical evidence, where patients are randomly assigned to treatment or control — found that CPAP use significantly reduces HbA1c in diabetic patients with OSA. HbA1c is the blood test that measures average blood glucose over the preceding three months, and it is the key marker by which diabetes management is assessed. The reduction was an average of 0.24 per cent. That may not sound large, but in the context of pharmacological glucose management, most diabetes medications achieve between 0.5 and 1 per cent reduction in HbA1c. A contribution of 0.24 per cent from treating the sleep problem — without medication side effects — is clinically meaningful, and it is proportional to nightly hours of CPAP use: more hours of use, greater blood glucose benefit.
How Sleep Apnoea Disrupts Insulin Sensitivity
Three mechanisms work simultaneously. First, intermittent nocturnal hypoxia — the repeated oxygen drops during apnoea events — directly impairs glucose metabolism and promotes insulin resistance through oxidative stress pathways. Second, sleep fragmentation independently reduces insulin sensitivity: studies of healthy adults who were subjected to deliberate sleep disruption without any hypoxia showed measurable insulin resistance within just a few days. Third, cortisol elevation from repeated arousal responses promotes gluconeogenesis (the liver producing extra glucose) and peripheral insulin resistance.
The consequence is that someone with untreated moderate-to-severe OSA is being metabolically stressed every night in ways that push glucose upward and insulin sensitivity downward. Even if their diet and exercise habits are otherwise excellent, the overnight metabolic insult is continuously working against them.
Fatty Liver Disease (NAFLD)
The connection between OSA and non-alcoholic fatty liver disease (NAFLD) — a condition where fat accumulates in the liver without excessive alcohol as a cause — is one of the more recent and well-characterised causal links in the field.
Observationally, OSA raises NAFLD risk by 115 per cent — an odds ratio of 2.15, meaning OSA patients are more than twice as likely to have NAFLD. Non-alcoholic fatty liver disease affects roughly 1 in 4 UK adults (about 25 per cent). With OSA, that rises to roughly 1 in 2. These are rough approximations for a high-prevalence condition, but they convey the scale of the effect.
A study using Mendelian randomisation — a method that uses people's genetic makeup as a kind of natural experiment to test whether one thing genuinely causes another, rather than simply occurring alongside it — confirmed that OSA causally increases the risk of NAFLD (odds ratio 1.50). This matters because it rules out the possibility that both conditions simply happen to be common in similar kinds of people. The OSA is independently driving the liver problem. The mechanism is that intermittent nocturnal hypoxia drives hepatic oxidative stress — a form of cellular damage in liver cells — independently of the dietary and weight factors that typically cause NAFLD. The severity of fatty liver correlates with OSA severity, and in children, OSA is associated with elevated liver enzymes and progressive hepatic fibrosis, suggesting the liver damage begins during childhood when OSA goes untreated. CPAP therapy stabilises or slows NAFLD progression in several studies, though it does not reliably reverse established fibrosis.
Mendelian randomisation studies confirm that sleep apnoea causally increases the risk of fatty liver disease, independent of obesity and diet. The liver is being damaged by what happens in the airway during sleep.
Weight and the Metabolic Trap
The weight-OSA relationship creates a clinical trap that many patients experience but few understand. OSA disrupts the hormones that regulate hunger and energy storage in a way that makes weight gain easier and weight loss harder. Leptin resistance means the brain does not receive the satiety signal from existing fat stores, so appetite remains elevated. Low adiponectin means the metabolic environment favours fat storage over fat oxidation. Elevated cortisol promotes specifically visceral (abdominal) fat deposition — the fat that carries the highest metabolic and cardiovascular risk. Disrupted sleep architecture reduces the motivation and physical energy required for exercise.
The practical consequence is that a patient told to lose weight in order to improve their OSA is being given advice that is correct in principle but extremely difficult to act on when the OSA is itself sabotaging the hormonal preconditions for successful weight loss. Treating the OSA first, or simultaneously, improves the metabolic environment within which weight management takes place. This is not an argument against weight loss, which genuinely reduces OSA severity. It is an argument for treating the sleep problem rather than treating it as purely secondary to weight.
Gut Microbiome
A newer but increasingly robust finding is that OSA measurably alters the composition of gut bacteria — the microbiome. OSA patients show reduced diversity of gut bacteria with elevated populations of Firmicutes and depleted Bacteroidetes — a pattern closely associated with metabolic disease, systemic inflammation, and cardiovascular risk. The mechanism appears to be OSA-driven intermittent hypoxia and circadian disruption altering the intestinal environment. This is an active area of research, and its full implications for metabolic disease management in OSA patients are still being characterised, but the direction of the effect is consistent with everything else described on this page.
References
[1] Wang C et al. Obstructive sleep apnea, prediabetes and progression of type 2 diabetes: a systematic review and meta-analysis. Journal of Diabetes Investigation. 2022. 25 studies, 154,948 patients; OR 2.29 for diabetes overall, OR 3.28 in patients under 50; dose-dependent relationship with severity.
[2] Huang Q et al. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes: a systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2024. 11 RCTs; CPAP significantly reduced HbA1c by 0.24% compared with control; effect proportional to nightly hours of use.
[3] Zhang Z et al. Causal relationship between sleep apnea and non-alcoholic fatty liver disease: a Mendelian randomization study. European Journal of Clinical Investigation. 2023. Bidirectional MR; univariable analysis showed OSA causally increases NAFLD risk (OR 1.50); association partially mediated by BMI.
[4] Umbro I et al. Association between non-alcoholic fatty liver disease and obstructive sleep apnea. World Journal of Gastroenterology. 2020. 13 observational studies, 2,753 participants; OR 2.15 for NAFLD in OSA patients; NAFLD severity correlated with OSA severity.
[5] Herth FJF et al. Prevalence of obstructive sleep apnea among patients with type 2 diabetes mellitus. Endocrine Practice. 2023. Systematic review; OSA found in 55-86% of T2D patients across studies.
[6] Guo X et al. Alterations in gut microbiota in patients with obstructive sleep apnea: a systematic review. Sleep Medicine. 2025. Systematic review; consistent finding of reduced microbiome diversity, elevated Firmicutes, depleted Bacteroidetes in OSA patients compared with controls.
Contact Professor Vik Veer
If you would like to discuss a sleep assessment or arrange a consultation, please use the details below.
Private secretary: 0207 458 4584